Dr. Shafique on Selecting Between Selpercatinib and Pralsetinib in RET+ NSCLC

May 4, 2021
Michael Shafique, MD

Partner | Cancer Centers | <b>Moffitt</b>

Michael Shafique, MD, discusses treatment considerations for selecting between selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer.

Michael Shafique, MD, medical oncologist, Department of Thoracic Oncology, Moffitt Cancer Center, discusses treatment considerations for selecting between selpercatinib (Retevmo) and pralsetinib (Gavreto) in RET fusion–positive non–small cell lung cancer (NSCLC).

Selpercatinib and pralsetinib are FDA approved RET inhibitors indicated for the frontline treatment of patients with RET fusion–positive NSCLC, says Shafique. Without head-to-head comparative data, it is difficult to determine whether one agent is optimal vs the other because both agents have demonstrated similar efficacy, central nervous system penetrance, and tolerability, Shafique explains.

Although selpercatinib and pralsetinib are associated with similar toxicities, including hypertension, subtle differences between the safety profiles may inform which agent a patient should receive, Shafique says. For example, selpercatinib appears to cause more QT interval changes vs pralsetinib, Shafique concludes.